Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador.
A total of 537 subjects were randomized to receive either SPf66 malaria vaccine against Plasmodium falciparum or placebo in three doses (days 0, 30 and 180). Subjects completing the course of vaccination (230 in the vaccine and 238 in the placebo group) were followed up for a further 12 months. Case detection surveillance was implemented by parasitological cross-sectional surveys every 2 months and by monthly household visits to each participant. Symptomatic subjects were also diagnosed in a local health centre. Minor local side-effects were observed mainly after the second dose in about 19% of the vaccinated subjects and in 3.7% of the placebo group. Thirty days after the third dose the prevalence of anti-SPf66 antibodies was 57% in the vaccine and 8.8% in the placebo groups. The prevaccination prevalence of antibodies measured by indirect immunofluorescence assay increased with age and seemed to be inversely related to anti-SPf66 antibody production. Immune response to SPf66 was independent of age. Vaccine efficacy was calculated based on person-time of exposure. The protective effect considering any malaria episode was 66.8% (95% confidence interval = -2.7-89.3%) and considering only one episode per individual was 60.2% (95% confidence interval = -26-87.5%).
Sempértegui
F
F
Instituto de Investigaciones para el Desarrollo de la Salud (IIDES), Ministerio de Salud Pública, Ecuador, Quito.
Estrella
B
B
Moscoso
J
J
Piedrahita
L
L
Hernández
D
D
Gaybor
J
J
Naranjo
P
P
Mancero
O
O
Arias
S
S
Bernal
R
R
D000293:Adolescent; D000328:Adult; D015551:Autoimmunity; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D004484:Ecuador; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D017780:Malaria Vaccines / Q000009:adverse effects / Q000276:immunology*; D016778:Malaria, Falciparum / Q000276:immunology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D015800:Protozoan Proteins / Q000009:adverse effects / Q000276:immunology*; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000276:immunology
D017780:Malaria Vaccines; D015800:Protozoan Proteins; D011994:Recombinant Proteins; C066269:SPf66 protein, Plasmodium; D014614:Vaccines, Synthetic